Blincyto (pembrolizumab): Risk of Medication Errors and Benzyl alcohol toxicity​.

Keytruda (pembrolizumab): Restriction of indication for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy.